Evidence map›Paper›PMID 34567162›Full record

ArticleIranian journal of pharmaceutical research : IJPR2021

Mohammad Yousef Memar, Khosro Adibkia, Safar Farajnia, Hossein Samadi Kafil, Younes Khalili, Robab Azargun, Reza Ghotaslou

Open access · greenAbstract read
In one paragraph

Article in Iranian journal of pharmaceutical research : IJPR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Identification ofVeterinary world · 2024
    Article
  9. Article
  10. The use of combination therapy for the improvement of colistin activity against bacterial biofilm.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024
    Review
  11. Article
  12. Intravenous Fosfomycin for Systemic Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2023
    Review
  13. Article
  14. Article
  15. Article
  16. Clinical Distribution and Drug Resistance ofJournal of clinical medicine · 2023
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Mohammad Yousef MemarInfectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Khosro AdibkiaResearch Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran.
Safar FarajniaDrug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Hossein Samadi KafilDepartment of Bacteriology and Virology, School of Medicine, Tabriz University of Medical Sciences, Iran.
Younes KhaliliImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Robab AzargunImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Reza GhotaslouInfectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Tabriz University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to investigate

Indexed as

BiofilmCarbapenem-resistantCombination therapyPseudomonas aeruginosasynergic

Identifiers

PMID34567162
PMCPMC8457740
OpenAlexW3184008094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.